Pascal Saremsky
Neurology with Special Qualifications in Child Neurology · Oceanside, NYNPI 1861767931
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 304 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$1K
- Corium, LLC$890
- Neurelis, Inc.$621
- Neos Therapeutics, LP$539
- Tris Pharma Inc$362
- Supernus Pharmaceuticals, Inc.$354
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 69 | $1,160 |
| Corium, LLC | 48 | $890 |
| Neurelis, Inc. | 25 | $621 |
| Neos Therapeutics, LP | 35 | $539 |
| Tris Pharma Inc | 20 | $362 |
| Supernus Pharmaceuticals, Inc. | 15 | $354 |
| Collegium Pharmaceutical, Inc. | 18 | $328 |
| UCB, Inc. | 14 | $291 |
| AbbVie(2 entities) | 13 | $263 |
| Sunovion Pharmaceuticals Inc. | 8 | $156 |
| Biomarin Pharmaceutical Inc. | 3 | $74 |
| Eisai Inc. | 3 | $62 |
| Avion Pharmaceuticals | 3 | $57 |
| Medtronic(2 entities) | 2 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Vertical Pharmaceuticals, LLC | 3 | $55 |
| Lilly USA, LLC | 2 | $40 |
| Bioventus LLC | 2 | $33 |
| Harmony Biosciences LLC | 2 | $29 |
| GSK | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Abbott | 1 | $24 |
| Adlon Therapeutics L.p. | 1 | $22 |
| Pfizer | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Almatica Pharma LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
| Merck | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Aquestive Therapeutics, Inc. | 1 | $16 |
| Melinta Therapeutics, LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Greenwich Biosciences, Inc. | 1 | $15 |
| Biogen | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$124
How this compares
$5,725 in reported general payments places this provider in the 80th percentile of 161 neurology with special qualifications in child neurology providers in New York.
See all neurology with special qualifications in child neurology providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 15 | $58 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Oceanside
- Claudia ChiribogaNew York$220K
- Eric SegalN White Plains$133K
- Kaleb YohayNew York$125K
- Heather LauNew York$103K
- Louis ManganasEast Setauket$86K
- Darryl DevivoNew York$67K
- Mary Lynn ChuNew York$66K
- Jonathan MinkRochester$54K
- Sanjeev KothareNew Hyde Park$53K
- Mohammad QasaymehAmherst$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.